AstraZeneca PLC
AZN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $54 | $46 | $44 | $37 |
| % Growth | 18% | 3.3% | 18.5% | – |
| Cost of Goods Sold | $10 | $8 | $12 | $12 |
| Gross Profit | $44 | $38 | $32 | $25 |
| % Margin | 81.1% | 82% | 72.1% | 66.8% |
| R&D Expenses | $14 | $11 | $10 | $10 |
| G&A Expenses | $20 | $18 | $17 | $15 |
| SG&A Expenses | $20 | $18 | $18 | $16 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $34 | $29 | $28 | $24 |
| Operating Income | $10 | $8 | $4 | $1 |
| % Margin | 18.5% | 17.9% | 8.5% | 2.8% |
| Other Income/Exp. Net | -$1 | -$1 | -$1 | -$1 |
| Pre-Tax Income | $9 | $7 | $3 | -$0 |
| Tax Expense | $2 | $1 | -$1 | -$0 |
| Net Income | $7 | $6 | $3 | $0 |
| % Margin | 13% | 13% | 7.4% | 0.3% |
| EPS | 1.14 | 1.91 | 1.06 | 0.04 |
| % Growth | -40.3% | 80.2% | 2,550% | – |
| EPS Diluted | 1.13 | 1.91 | 1.06 | 0.04 |
| Weighted Avg Shares Out | 3 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 3 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $1 | $1 |
| Depreciation & Amortization | $5 | $5 | $5 | $4 |
| EBITDA | $15 | $13 | $9 | $5 |
| % Margin | 28.6% | 29.3% | 20.5% | 13.7% |